Ketamine Infusion denials in California external review

In the California DMHC record, independent physician reviewers decided 29 published external-review cases involving Ketamine Infusionand overturned the plan’s denial in 31%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.

California DMHC decisions
29
2009–2025
Overturned
31%
9 denials reversed

By condition

Published outcomes when Ketamine Infusion was denied for these conditions.
ConditionDecisionsOverturned
Complex Regional Pain Syndrome17
29.4%

What the insurer actually argued

Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
Reason givenDecisionsOverturned
Experimental/Investigational
The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument.
20
25%
Medical Necessity
The plan said the care wasn’t medically necessary. The most common fight, and the most winnable.
9
44.4%
Typical time to a decision
13 days
Most land between 7 and 21 days
Handled as urgent
58.6%
Expedited when a delay would cause harm

What the reviewers wrote

Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for inpatient Ketamine infusion, continuous for five to seven days. Ketamine infusions are an effective treatment option for complex regional pain syndrome (CRPS) that is refractory to standard treatments such as medications, sympathetic nerve blocks, therapy, and multidisciplinary care. Researchers report that in a systematic review, 13 of 14 studies reviewed found that Ketamine infusions resulted in a decrease in pain scores and relief of symptoms.
Experimental/Investigational · 2023 · IMR EI23-38618
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for inpatient Ketamine infusion, continuous for five to seven days. Ketamine infusions are an effective treatment option for complex regional pain syndrome (CRPS) that is refractory to standard treatments such as medications, sympathetic nerve blocks, therapy, and multidisciplinary care. One study found that Ketamine infusions resulted in a decrease in pain scores and relief of symptoms. Similarly, another study found that Ketamine treatment led to a decreased mean pain score in comparison to the self-controlled baseline and that Ketamine infusions could provide clinically effective pain relief in the short-term for less than three months.
Experimental/Investigational · 2023 · IMR EI23-39686

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for a series of Ketamine infusions. The records reflect that this patient has a history of complex regional pain syndrome (CRPS) which has been refractory to medication management, acupuncture, chiropractic care, and interventional procedures. In a meta-analysis of the current medical literature regarding the effects of Ketamine infusion for treating CRPS, authors found that Ketamine treatment led to a decreased mean pain score in comparison to the self-controlled baseline. However, the authors further noted, “Our findings suggested that Ketamine infusion can provide clinically effective pain relief in short term for less than three months.
Experimental/Investigational · 2023 · IMR EI23-40344
ature of Statutory Criteria/Case Summary: The patient is a 53-year-old female diagnosed with complex regional pain syndrome (CRPS) involving the left foot. Findings: The physician reviewer found that the patient underwent left gastrocnemius tendon recession, left foot subtalar arthrodesis, left first ray bunionectomy, left fifth toe hammer toe surgery, and left navicular resection with tendon interposition. A report dated 1/31/19 noted that the patient developed compartment syndrome a few days after the surgery and was treated in the emergency department and discharged. When her cast was removed, she developed severe post-operative pain, sensitivity to cold, touch, numbness, and inability to bear weight on the left foot that gradually worsened to the extent that she was unable to walk.
Medical Necessity · 2019 · IMR MN19-30635

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.

How to use this in your appeal

These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Ketamine Infusion, then check the rights and deadlines that apply to your plan.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Denied Ketamine Infusion? Use the California record to prepare.

Explain my denial — freeStart my appeal · $39